行情

CTMX

CTMX

CytomX医疗
NASDAQ

实时行情|Nasdaq Last Sale

6.99
-0.63
-8.27%
已收盘, 16:00 08/11 EDT
开盘
7.72
昨收
7.62
最高
7.72
最低
6.98
成交量
62.24万
成交额
--
52周最高
15.44
52周最低
3.595
市值
3.21亿
市盈率(TTM)
-5.0829
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CTMX价格均价为13.44,最高价位18.00,最低价为9.00。

EPS

CTMX 新闻

更多
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 4天前
CytomX EPS misses by $0.83, misses on revenue
CytomX (NASDAQ:CTMX): Q2 GAAP EPS of -$0.34 misses by $0.83. Revenue of $16.61M (+84.4% Y/Y) misses by $36.38M. Shares -1.6%. Press Release
seekingalpha · 5天前
CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneeri
GlobeNewswire · 5天前
CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therape
GlobeNewswire · 08/04 12:00
CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
CytomX Therapeutics to Announce Second Quarter 2020 Financial Results
-Teleconference Scheduled for August 6, 2020, at 5:30 p.m. ET-SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of inves
GlobeNewswire · 07/28 12:00
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - July 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) of the July 20, 2020 deadline to seek the role of le
Newsfile · 07/18 03:24
2 Top Cancer Treatment Stocks To Watch In July
MotleyFool.com · 07/14 15:14

所属板块

生物技术和医学研究
-2.24%
制药与医学研究
-0.89%

热门股票

代码
价格
涨跌幅

CTMX 简况

CytomX Therapeutics, Inc.是一家专注于肿瘤科的生物制药公司。该公司基于其“Probody”技术平台从事抗体疗法的开发业务。该公司利用其平台开发针对临床验证目标的免疫治疗方案并开发治疗不同癌症的疗法。“Probody”疗法包括通过标准抗体生产方法生产的三大成分(作为单一蛋白)。这三大成分包括活性癌症抗体、抗体屏蔽物以及蛋白酶易劈链接。“Probody”候选产品CX-072靶向程序性死亡因子配体1(PD-L1)。CX-072依照靶向PD-L1的单克隆抗体制造。其候选产品CX-2009靶向CD-166。该公司正在开发一种程序性细胞死亡蛋白1(PD-1)“Probody”疗法,用于封锁PD-L1或PD-1通路。该公司还开展整合素alpha3抗原“Probody”药物结合物(PDC)计划。
展开

微牛提供CytomX Therapeutics Inc(NASDAQ-CTMX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CTMX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CTMX股票基本功能。